CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are frequently discussed together — and often used in combination — for growth hormone optimization. They work through complementary mechanisms, which is why the combination is one of the most popular peptide pairings. Understanding how each works individually helps explain why they are often paired.
CJC-1295 and Ipamorelin are the two halves of the most popular growth-hormone peptide stack. CJC-1295 "turns up the volume" on your body's GHRH signal; Ipamorelin "presses play" on a separate ghrelin-receptor pathway. Together they produce more GH release than either alone, with Ipamorelin's selectivity keeping side effects cleaner than older alternatives.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
| Category | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism | GHRH receptor agonist (amplifies GH release signal) | Ghrelin receptor agonist (triggers GH release) |
| Evidence Level | Moderate — Phase II clinical trials exist | Moderate — human pharmacodynamic studies exist |
| Selectivity | Specific to GHRH pathway | Highly selective — minimal cortisol/prolactin effects |
| Half-Life | With DAC: ~6-8 days. Without DAC: ~30 minutes | ~2 hours |
| Common Side Effects | Water retention, tingling, flushing | Mild water retention, head rush, increased appetite |
| Typical Use | Often combined with Ipamorelin | Often combined with CJC-1295 |
In depth
Two pathways, one goal
CJC-1295 and Ipamorelin both end up raising your growth hormone — but they hit different receptors on the way there, which is the entire reason the pairing works. CJC-1295 is a modified GHRH analog: it binds the growth-hormone-releasing-hormone receptor on your pituitary and amplifies the signal your hypothalamus is already sending. Ipamorelin is a ghrelin-mimetic: it binds the ghrelin/GHS-R receptor on a parallel pathway, triggering a discrete GH pulse. Think of CJC-1295 as turning up the volume on the GH signal and Ipamorelin as hitting "play" on the release event itself. Fire both and the combined GH output is greater than either peptide produces alone.
Why Ipamorelin, specifically
Ipamorelin didn't become the default ghrelin-mimetic by accident. Earlier peptides in the same family (GHRP-2, GHRP-6, hexarelin) also trigger GH release, but they're notorious for also spiking cortisol, prolactin, and hunger. Ipamorelin is prized for being clean — it stimulates GH without meaningfully activating those other axes. That selectivity is why CJC-1295 + Ipamorelin is considered one of the better-tolerated GH-optimization protocols in the peptide space.
What to expect
Users commonly report improvements in sleep depth (GH release is linked to slow-wave sleep), recovery, and gradual body composition shifts over 2–3 months. IGF-1 — the downstream marker of GH activity — typically rises on labs within a few weeks of consistent dosing. The injection is small, subcutaneous, and typically timed before bed so the peptide-induced GH pulse aligns with the natural sleep-onset pulse. Side effects when they occur are usually mild: injection site flushing, transient water retention, occasional numbness or tingling.
Bottom line
The question is rarely "CJC-1295 or Ipamorelin" — it's "how do I stack them." Used individually, each peptide has real activity, but the combination is where the mainstream biohacking protocol sits. There's still a decision buried in CJC-1295 itself (with DAC vs. without DAC — see that separate comparison), but the partnership with Ipamorelin is the consistent part. Any GH-axis intervention should be under clinician supervision with IGF-1, fasting glucose, and periodic body-composition monitoring.
These peptides are often used together. See our stack profiles for combination details.